Cardiac Ca2+ signaling and Ca2+ sensitizers

Circulation Journal

Volumn 72, Issue 12, 2008, Pages 1915-1925

  Endoh, Masao ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Calcium; Congestive heart failure; Excitation contraction (E C) coupling; Inotropic agents; Myocardial contraction

Indexed keywords

1,3,5,6 TETRAHYDRO 5 METHYL 6 PHENYL 3,6 METHANO 1,5 BENZODIAZOCINE 2,4 DIONE; 5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; 6 [1 [2 (4 CYANOPHENYL) 2 HYDROXYETHYL] 1,2,5,6 TETRAHYDRO 4 PYRIDYL] 4,5 DIHYDRO 3(2H) PYRIDAZINONE; ADRENERGIC RECEPTOR; AEQUORIN; ALPHA ADRENERGIC RECEPTOR; AMRINONE; ANGIOTENSIN; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR; CALCIUM SENSITIZER; DIGITALIS; ENDOTHELIN 1; ENOXIMORE; FLUORESCENT DYE; ISOBUTYLMETHYLXANTHINE; ISOPRENALINE; LEVOSIMENDAN; MILRINONE; MUSCARINIC RECEPTOR; N HYDROXY 5,6 DIMETHOXY 2 BENZO[B]THIOPHENECARBOXIMIDAMIDE; ORPRINONE; PHOSPHODIESTERASE III INHIBITOR; PIMOBENDAN; PIROXIMORE; TROPONIN C; UNCLASSIFIED DRUG; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AZOCINE DERIVATIVE; BA 41899; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM; CARDIOTONIC AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIHYDROPYRIDINE DERIVATIVE; ENDOTHELIN; HYDRAZONE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PYRIDAZINE DERIVATIVE; QUINOLINE DERIVATIVE; SIMENDAN; THIADIAZINE DERIVATIVE;

CALCIUM SIGNALING; CONGESTIVE HEART FAILURE; DRUG BINDING; DRUG MECHANISM; ENERGY TRANSFER; EXCITATION; EXCITATION CONTRACTION COUPLING; HUMAN; INOTROPISM; ISCHEMIC HEART DISEASE; MOBILIZATION; MUSCLE CELL; MUSCLE CONTRACTILITY; NONHUMAN; REVIEW; SENSITIZATION; STARLING LAW; STIMULATION; THIN FILAMENT; ANIMAL; DRUG EFFECT; HEART CONTRACTION; HEART FAILURE; HEART MUSCLE; METABOLISM; PATHOPHYSIOLOGY;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-AGONISTS; ANGIOTENSIN II; ANIMALS; AZOCINES; CALCIUM; CALCIUM SIGNALING; CARDIOTONIC AGENTS; CHOLINERGIC AGONISTS; DIHYDROPYRIDINES; ENDOTHELINS; HEART FAILURE; HUMANS; HYDRAZONES; MYOCARDIAL CONTRACTION; MYOCARDIUM; PHOSPHODIESTERASE INHIBITORS; PYRIDAZINES; QUINOLINES; THIADIAZINES; TROPONIN C;

EID: 56849111197     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0838     Document Type: Review

References (71)

1. Endoh M. Force-frequency relationship in intact mammalian ventricular myocardium: Physiological and pathophysiological relevance. Eur J Pharmacol 2004; 500: 73-86.
2. 2+ signaling in intact myocardium. J Pharmacol Sci 2006; 100: 525-537.
3. Allen DG, Blinks JR. Calcium transients in aequorin-injected frog cardiac muscle. Nature 1978; 273: 509-513.
4. ++ as an inotropic mechanism. Circulation 1986; 73: III-85-III-98.
5. 2+ concentrations in living cells. Prog Biophys Mol Biol 1982; 40: 1-114.
6. Abe F, Mitsui M, Karaki H, Endoh M. Calcium compartments in vascular smooth muscle as detected by aequorin signal. Br J Pharmacol 1995; 116: 3000-3004.
7. 2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol 1998; 30: 1115-1128.
8. Talukder MAH, Norota I, Sakurai K, Endoh M. Inotropic response of rabbit ventricular myocytes to endothelin-1: Difference from isolated papillary muscles. Am J Physiol 2001; 281: H596-H605.
9. 2+ mediated through α-and β-adrenoceptors. Circ Res 1988; 62: 247-265.
10. Allen DG, Kurihara S. The effects of muscle length on intracellular calcium transients in mammalian cardiac muscle. J Physiol 1982; 327: 79-94.
11. Fukuda N, Granzier HL. Titin/connectin-based modulation of the Frank-Starling mechanism of the heart. J Muscle Res Cell Motil 2005; 26: 319-323.
12. Schwinger RH, Böhm M, Koch A, Schmidt U, Morano I, Eissner HJ, et al. The failing human heart is unable to use the Frank-Starling mechanism. Circ Res 1994; 74: 959-969.
13. Endoh M. Frequency-dependent inhibition of the intracellular calcium transients by calmodulin antagonists in the aequorin-injected rabbit papillary muscle. Adv Exp Med Biol 1989; 255: 461-470.
14. Schwinger RH, Böhm M, Müller-Ehmsen J, Uhlmann R, Schmidt U, Stablein A, et al. Effect of inotropic stimulation on the negative force-frequency relationship in the failing human heart. Circulation 1993; 88: 2267-2276.
15. Endoh M. The effects of various drugs on myocardial inotropic response. Gen Pharmacol 1995; 26: 1-31.
16. 2+ sensitization as mechanisms of action of physiological interventions and inotropic agents in intact myocardial cells. Jpn Heart J 1998; 39: 1-44.
17. Endoh M. Cardiac α-adrenoceptors that regulate contractile function: Subtypes and subcellular transduction mechanisms. Neurochem Res 1996; 21: 217-229.
18. th edn. London: Academic Press; 2001; 609-631.
19. 2+ transients and contractility in rabbit ventricular myocardium. Life Sci 1998; 62: 1485-1489.
20. 2+ signaling in mammalian atrial and ventricular myocardium. Eur J Pharmacol 1999; 375: 177-196.
21. Endoh M, Hori M. Basic pharmacology and clinical application of new positive inotropic agents. Drugs Today 1993; 29: 29-56.
22. Endoh M. The therapeutic potential of novel cardiotonic agents. Expert Opin Invest Drugs 2003; 12: 735-750.
23. Endoh M, Hori M. Acute heart failure: Inotropic agents and their clinical uses. Expert Opin Pharmacother 2006; 7: 2179-2202.
24. Endoh M, Takanashi M, Norota I, Kawabata Y, Asano T. Pronounced direct inhibitory action mediated by adenosine A receptor and pertussis toxin-sensitive G protein on the ferret ventricular contraction. Naunyn-Schmiedeberg's Arch Pharmacol 1993; 348: 282-289.
25. Endoh M, Yanagisawa T, Taira N, Blinks JR. Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle. Circulation 1986; 73: III-117-III-133.
26. Endoh M. Correlation of cyclic AMP and cyclic GMP levels with changes in contractile force of dog ventricular myocardium during cholinergic antagonism of positive inotropic actions of histamine, glucagon, theophylline and papaverine. Jpn J Pharmacol 1979; 29: 855-864.
27. Endoh M. The time course of changes in cyclic nucleotide levels during cholinergic inhibition of positive inotropic actions of isoprenaline and theophylline in the isolated canine ventricular myocardium. Naunyn- Schmiedeberg's Arch Pharmacol 1980; 312: 175-182.
28. Chu L, Norota I, Ishii K, Endoh M. Inhibitory action of the phosphatase inhibitor cantharidin on the endothelin-1induced and the carbachol-induced negative inotropic effect in the canine ventricular myocardium. J Cardiovasc Pharmacol 2003; 41(Suppl 1): S89-S92.
29. Takanashi M, Endoh M. Characterization of positive inotropic effect of endothelin on mammalian ventricular myocardium. Am J Physiol 1991; 261: H611-H619.
30. Yang HT, Zhu Y, Endoh M. Species-dependent differences in inotropic effects and phosphoinositide hydrolysis induced by endothelin-3 in mammalian ventricular myocardium. Br J Pharmacol 1997; 120: 1497-1504.
31. Kasai H, Takanashi M, Takasaki C, Endoh M. Pharmacological properties of endothelin receptor subtypes mediating positive inotropic effects in rabbit heart. Am J Physiol 1994; 266: H2220-H2228.
32. Takanashi M, Endoh M. Concentration- and time-dependence of phosphoinositide hydrolysis induced by endothelin-1 in relation to the positive inotropic effect in the rabbit ventricular myocardium. J Pharmacol Exp Ther 1992; 262: 1189-1194.
33. Endoh M, Norota I, Yang HT, Fujita S. The positive inotropic effect and the hydrolysis of phosphoinositide induced by endothelin-3 in rabbit ventricular myocardium: Inhibition by a selective antagonist of ETA receptor, FR139317. J Pharmacol Exp Ther 1996; 277: 61-70.
34. 2+ sensitivity in rabbit ventricular myocytes. Eur J Pharmacol 2001; 424: 91-96.
35. 2+ transient and contractility in rabbit ventricular myocytes: Pharmacological analysis with KB-R7943. Br J Pharmacol 1999; 126: 1785-1795.
36. 2+ signalling in rabbit ventricular myocytes. Br J Pharmacol 2000; 131: 638-644.
37. Zhu Y, Yang HT, Endoh M. Negative chronotropic and inotropic effects of endothelin isopeptides in mammalian cardiac muscle. Am J Physiol 1997; 273: H119-H127.
38. 2+ current in rabbit ventricular myocytes. Naunyn-Schmiedeberg's Arch Pharmacol 1999; 360: 654-664.
39. 2+ current in dog ventricular myocytes. J Cardiovasc Pharmacol 2000; 36: 344-350.
40. 2+ signaling in contractile regulation induced by crosstalk between endothelin-1 and norepinephrine in dog ventricular myocardium. Circ Res 2003; 92: 1024-1032.
41. Chu L, Zhang JX, Norota I, Endoh M. Differential action of tyrosine kinase inhibitor, genistein, on the positive inotropic effect of endothelin-1 and norepinephrine in canine ventricular myocardium. Br J Pharmacol 2005; 144: 430-442.
42. 2+ sensitization induced by endothelin-1. Eur J Pharmacol 2005; 507: 135-143.
43. 2+ transients induced by endothelin-1 in rabbit ventricular myocytes. Naunyn-Schmiedeberg's Arch Pharmacol 2005; 371: 185-194.
44. Sakurai K, Norota I, Tanaka H, Kubota I, Tomoike H, Endoh M. Negative inotropic effects of angiotensin II, endothelin-1 and phenylephrine in indo-1 loaded adult mouse ventricular myocytes. Life Sci 2002; 70: 1173-1184.
45. Nishimaru K, Miura Y, Endoh M. Mechanisms of endothelin-1-induced decrease in contractility in adult mouse ventricular myocytes. Br J Pharmacol 2007; 152: 456-463.
46. 2+ transients and cell shortening in mouse ventricular myocytes. J Mol Cell Cardiol 2008; 44: 520-526.
47. Ishihata A, Endoh M. Pharmacological characteristics of the positive inotropic effect of angiotensin II in the rabbit ventricular myocardium. Br J Pharmacol 1993; 108: 999-1005.
48. Ishihata A, Endoh M. Species-related differences in inotropic effects of angiotensin II in mammalian ventricular muscle: Receptors, subtypes and phosphoinositide hydrolysis. Br J Pharmacol 1995; 114: 447-453.
49. 2+ transient induced by angiotensin II in isolated adult rabbit ventricular myocytes. Naunyn-Scmiederberg's Arch Pharmacol 1999; 360: 575-584.
50. 2+ transient and contractile force by angiotensin II in aequorin-loaded rabbit ventricular myocardium. Cardiovasc Res 1998; 37: 524-531.
51. 2+ current in gramicidin D-performed adult rabbit ventricular myocytes: Comparison with conventional patch-clamp method. Plungers Arch 2002; 444: 107-116.
52. + exchange to the positive inotropic effect of phenylephrine, endothelin-3 and angiotensin II in rabbit ventricular myocardium. Naunyn-Schmiedeberg's Arch Pharmacol 1997; 355: 87-96.
53. 2+ sensitizers: Update 2001. Cardiovasc Drugs Ther 2001; 15: 397-403.
54. Endoh M. Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol 2002; 40: 323-338.
55. 2+ sensitizing effect of (+)-enantiomer EMD 57033 on diastolic function but not on systolic function in rabbit ventricular cardiomyocytes. Jpn J Pharmacol 1999; 80: 55-65.
56. Solaro RJ, Gambassi G, Warshaw DM, Keller MR, Spurgeon HA, Beier N, et al. Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circ Res 1993; 73: 981-990.
57. 2+ sensitizer EMD 57033 and cardiac troponin I inhibitory peptide. Biochemistry 2000; 39: 8782-8790.
58. Sugawara H, Sakurai K, Atsumi H, Nakada S, Tomoike H, Endoh M. Differential alteration of cardiotonic effects of EMD 57033 and β-adrenoceptor agonists in volume-overload rabbit ventricular myocytes. J Card Fail 2000; 6: 338-349.
59. Kawabata Y, Endoh M. Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ Res 1993; 72: 597-606.
60. 2+ sensitizer Org-30029 reverses acidosis- and BDM-induced contractile depression in canine myocardium. Am J Physiol 1996; 271: H1829-H1839.
61. ++ sensitizer with no chronotropic activity in mammalian cardiac muscle. J Pharmacol Exp Ther 1998; 287: 214-222.
62. 2+ sensitizer. Cardiovasc Drug Rev 2001; 19: 345-368.
63. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998; 98: 2141-2147.
64. 2+ sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium. Br J Pharmacol 2005; 145: 1143-1152.
65. Takahashi R, Talukder MAH, Endoh M. Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium. J Cardiovasc Pharmacol 2000; 36: 118-125.
66. Takahashi R, Talukder MAH, Endoh M. Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. Eur J Pharmacol 2000; 400: 103-112.
67. 2+ transients under acidotic condition in aequorin-loaded canine ventricular myocardium. Naunyn-Schmiedeberg's Arch Pharmacol 2002; 366: 440-448.
68. Endoh M, Shibasaki T, Satoh H, Norota I, Ishihata A. Different mechanisms involved in the positive inotropic effects of benzimidazole derivative UD-CG 115 BS (pimobendan) and its demethylated metabolite UD-CG 212 Cl in canine ventricular myocardium. J Cardiovasc Pharmacol 1991; 17: 365-375.
69. 2+ sensitivity induced by UD-CG 212 Cl, an active metabolite of pimobendan, in canine ventricular myocardium. J Cardiovasc Pharmacol 2001; 37: 209-218.
70. 2+- sensitizing effect of UD-CG 212 Cl, a metabolite of pimobendan, under acidotic condition in canine ventricular myocardium. J Pharmacol Exp Ther 2001; 298: 1060-1066.
71. Endoh M. Regulation of myocardial contractility by a downstream mechanism. Circ Res 1998; 83: 230-232.